Cell therapy for kidney injury

Different options and mechanisms - Mesenchymal and amniotic fluid stem cells

Marina Morigi, Paolo De Coppi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Acute kidney injury (AKI) is emerging as a public health problem in developing and developed countries. It affects up to 7% of hospitalized patients, with a higher prevalence in critical care units. Despite major advances in preventive strategies and support measures, the mortality rate among patients remains higher than 50%. Several pharmacological approaches to improve renal function and survival after an AKI episode have been largely unsuccessful in clinical practice. Summary: Stem cell-based therapy has provided new hopes of innovative interventions to enhance the limited capability of kidney regeneration in AKI. An important target for cell therapy is represented by tubular epithelial cells which after acute ischemic or toxic insults undergo dysfunction and detachment. Among adult stem cells, mesenchymal stromal/stem cells (MSC) are an attractive therapeutic tool by virtue of their unique biological properties, tropism for damaged tissues, and proregenerative capacity. In the present review, we discuss the mechanisms underlying the renoprotective effects of therapies with stem cells of different origins in preclinical models of AKI by evaluating new modalities by which MSC interact with damaged cells via the release of soluble factors and exosomes/ microvesicles. Several biological effects, including antiapoptotic, promitogenic, immunomodulatory, and anti-inflammatory activities, have been analyzed in renal tissue of AKI animals receiving stem cell treatments. The mechanisms of stem cell homing and engraftment to sites of tissue damage have also been discussed. Key Messages: The translation of preclinical data on stem cells into effective and safe new modalities of care is still limited, and further studies are needed before their application in patients with AKI.

Original languageEnglish
Pages (from-to)59-63
Number of pages5
JournalNephron - Experimental Nephrology
Volume126
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Amniotic Fluid
Cell- and Tissue-Based Therapy
Acute Kidney Injury
Stem Cells
Mesenchymal Stromal Cells
Kidney
Wounds and Injuries
Exosomes
Adult Stem Cells
Tropism
Poisons
Critical Care
Developed Countries
Developing Countries
Regeneration
Anti-Inflammatory Agents
Therapeutics
Public Health
Epithelial Cells
Pharmacology

Keywords

  • Acute kidney injury
  • Amniotic fluid
  • Stem cells

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Genetics
  • Medicine(all)

Cite this

Cell therapy for kidney injury : Different options and mechanisms - Mesenchymal and amniotic fluid stem cells. / Morigi, Marina; De Coppi, Paolo.

In: Nephron - Experimental Nephrology, Vol. 126, No. 2, 2014, p. 59-63.

Research output: Contribution to journalArticle

@article{8441c65388fb4da7b6f523d6e3f64100,
title = "Cell therapy for kidney injury: Different options and mechanisms - Mesenchymal and amniotic fluid stem cells",
abstract = "Background: Acute kidney injury (AKI) is emerging as a public health problem in developing and developed countries. It affects up to 7{\%} of hospitalized patients, with a higher prevalence in critical care units. Despite major advances in preventive strategies and support measures, the mortality rate among patients remains higher than 50{\%}. Several pharmacological approaches to improve renal function and survival after an AKI episode have been largely unsuccessful in clinical practice. Summary: Stem cell-based therapy has provided new hopes of innovative interventions to enhance the limited capability of kidney regeneration in AKI. An important target for cell therapy is represented by tubular epithelial cells which after acute ischemic or toxic insults undergo dysfunction and detachment. Among adult stem cells, mesenchymal stromal/stem cells (MSC) are an attractive therapeutic tool by virtue of their unique biological properties, tropism for damaged tissues, and proregenerative capacity. In the present review, we discuss the mechanisms underlying the renoprotective effects of therapies with stem cells of different origins in preclinical models of AKI by evaluating new modalities by which MSC interact with damaged cells via the release of soluble factors and exosomes/ microvesicles. Several biological effects, including antiapoptotic, promitogenic, immunomodulatory, and anti-inflammatory activities, have been analyzed in renal tissue of AKI animals receiving stem cell treatments. The mechanisms of stem cell homing and engraftment to sites of tissue damage have also been discussed. Key Messages: The translation of preclinical data on stem cells into effective and safe new modalities of care is still limited, and further studies are needed before their application in patients with AKI.",
keywords = "Acute kidney injury, Amniotic fluid, Stem cells",
author = "Marina Morigi and {De Coppi}, Paolo",
year = "2014",
doi = "10.1159/000360667",
language = "English",
volume = "126",
pages = "59--63",
journal = "Nephron - Experimental Nephrology",
issn = "1660-8151",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Cell therapy for kidney injury

T2 - Different options and mechanisms - Mesenchymal and amniotic fluid stem cells

AU - Morigi, Marina

AU - De Coppi, Paolo

PY - 2014

Y1 - 2014

N2 - Background: Acute kidney injury (AKI) is emerging as a public health problem in developing and developed countries. It affects up to 7% of hospitalized patients, with a higher prevalence in critical care units. Despite major advances in preventive strategies and support measures, the mortality rate among patients remains higher than 50%. Several pharmacological approaches to improve renal function and survival after an AKI episode have been largely unsuccessful in clinical practice. Summary: Stem cell-based therapy has provided new hopes of innovative interventions to enhance the limited capability of kidney regeneration in AKI. An important target for cell therapy is represented by tubular epithelial cells which after acute ischemic or toxic insults undergo dysfunction and detachment. Among adult stem cells, mesenchymal stromal/stem cells (MSC) are an attractive therapeutic tool by virtue of their unique biological properties, tropism for damaged tissues, and proregenerative capacity. In the present review, we discuss the mechanisms underlying the renoprotective effects of therapies with stem cells of different origins in preclinical models of AKI by evaluating new modalities by which MSC interact with damaged cells via the release of soluble factors and exosomes/ microvesicles. Several biological effects, including antiapoptotic, promitogenic, immunomodulatory, and anti-inflammatory activities, have been analyzed in renal tissue of AKI animals receiving stem cell treatments. The mechanisms of stem cell homing and engraftment to sites of tissue damage have also been discussed. Key Messages: The translation of preclinical data on stem cells into effective and safe new modalities of care is still limited, and further studies are needed before their application in patients with AKI.

AB - Background: Acute kidney injury (AKI) is emerging as a public health problem in developing and developed countries. It affects up to 7% of hospitalized patients, with a higher prevalence in critical care units. Despite major advances in preventive strategies and support measures, the mortality rate among patients remains higher than 50%. Several pharmacological approaches to improve renal function and survival after an AKI episode have been largely unsuccessful in clinical practice. Summary: Stem cell-based therapy has provided new hopes of innovative interventions to enhance the limited capability of kidney regeneration in AKI. An important target for cell therapy is represented by tubular epithelial cells which after acute ischemic or toxic insults undergo dysfunction and detachment. Among adult stem cells, mesenchymal stromal/stem cells (MSC) are an attractive therapeutic tool by virtue of their unique biological properties, tropism for damaged tissues, and proregenerative capacity. In the present review, we discuss the mechanisms underlying the renoprotective effects of therapies with stem cells of different origins in preclinical models of AKI by evaluating new modalities by which MSC interact with damaged cells via the release of soluble factors and exosomes/ microvesicles. Several biological effects, including antiapoptotic, promitogenic, immunomodulatory, and anti-inflammatory activities, have been analyzed in renal tissue of AKI animals receiving stem cell treatments. The mechanisms of stem cell homing and engraftment to sites of tissue damage have also been discussed. Key Messages: The translation of preclinical data on stem cells into effective and safe new modalities of care is still limited, and further studies are needed before their application in patients with AKI.

KW - Acute kidney injury

KW - Amniotic fluid

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84901421415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901421415&partnerID=8YFLogxK

U2 - 10.1159/000360667

DO - 10.1159/000360667

M3 - Article

VL - 126

SP - 59

EP - 63

JO - Nephron - Experimental Nephrology

JF - Nephron - Experimental Nephrology

SN - 1660-8151

IS - 2

ER -